Immunomodulation

A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

BACKGROUND

Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal five-year survival rate of 13% and is closely associated with cachexia. Cancer cachexia is a multifactorial syndrome characterized by irreversible wasting of skeletal muscles, fat loss and systemic inflammation. While cachexia is known...

🗓️ 2026-02-27
Read MoreA Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

Cancer cachexia is the prototypical example of comorbidity, occurring in most of cancer patients. It is a direct consequence of tumor growth and of the associated inflammatory/immune response. Cachexia can be exacerbated by anti-cancer therapies, frequently resulting in dose limitation...

🗓️ 2024-09-10
📰 Publication: Molecular Aspects Of Medicine
Read MoreImmunomodulation: A new approach to cancer cachexia, potentially suitable for aging.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!